Prognostic Factors in Patients with Localized Soft Tissue Sarcoma

국소 연조직 환자의 예후인자 분석

  • Koh, Sung-Ae (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Lee, Kyung-Hee (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Kim, Min-Kyoung (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Hyun, Myung-Soo (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Shin, Duk-Seop (Department of Orthopedic Surgery, Yeungnam University College of Medicine) ;
  • Yun, Sang-Mo (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kang, Min-Kyu (Department of Radiation Oncology, Yeungnam University College of Medicine)
  • 고성애 (영남대학교 의과대학 내과학교실) ;
  • 이경희 (영남대학교 의과대학 내과학교실) ;
  • 김민경 (영남대학교 의과대학 내과학교실) ;
  • 현명수 (영남대학교 의과대학 내과학교실) ;
  • 신덕섭 (영남대학교 의과대학 정형외과학교실) ;
  • 윤상모 (영남대학교 의과대학 방사선종양학교실) ;
  • 강민규 (영남대학교 의과대학 방사선종양학교실)
  • Published : 2011.04.01

Abstract

Background/Aims: We evaluated the independent prognostic factors for overall and disease-free survival in the treatment of soft tissue sarcoma. Methods: Sixty-seven medical records were retrospectively reviewed. All the patients had presented with localized soft tissue sarcoma and had been treated with conservative surgery, followed by additional therapy or surgery. All were treated at the Yeungnam University Hospital between January 2000 and December 2006. Univariate and multivariate analyses were used to evaluate factors affecting overall and disease-free survival. Results: The median age of the study sample was 50 (range, 15~70) years. Twenty patients (30%) had liposarcoma and nine (13%) had leiomyosarcoma. Seventeen patients (25%) had a tumor measuring greater than 10 cm. Nineteen patients (28%) had positive resection margins. The median overall survival was 62.7 months (95% CI: 25.7~99.4) and the median disease-free survival was 36.1 months (95% CI: 17.9~54.2). Factors that significantly affected the median overall survival were a tumor size greater than 10 cm and performance status. Positive resection margins and tumor site were independent prognostic factors associated with disease-free survival. Other factors, such as histopathology, gender, age, and tumor grade, did not have prognostic value. Additionally, the chosen modality of treatment after surgery was not an independent predictor of the median overall or disease-free survival. Conclusions: Tumor size, positive resection margins, tumor site, and performance status were statistically significant independent predictors of poor prognosis.

목적: 연부조직 육종이란 지방, 근육, 신경, 섬유성 관절, 혈관이나 피부의 깊은 조직으로부터 생기는 악성종양이다. 예후를 예측할 수 있는 인자에 대한 분석도 많지 않은데, 현재 국소재발과 관련된 예후인자로 나이, 후복막과 두부에 종양이 위치했을 때, 종양의 등급, 특정한 조직분류가 보고되고 있다. 방법: 이 연구는 2000년 1월부터 2006년 12월까지 영남대학병원에 입원하여 국소적인 연부조직 육종을 진단받고 단독수술 혹은 수술 후 병합치료를 시행한 환자를 선정하여 의무기록을 후향적으로 조사하였다. 나이, 성별, 종양의 위치, 종양의 조직종류, 수술절제 단면의 암세포의 유무, 수술, 항암요법, 방사선 요법 등의 치료 종류 등을 포함한 환자의 특징을 포함시켰다. 전체 생존기간과 무병 생존기간에 연관있는 여러 인자들을 단변량 분석과 다변량 분석을 사용하여 분석하였다. 결과: 환자들의 일반적인 특징을 보면, 평균나이는 50세(범위 17~70세)였다. 남녀 비율은 남자 31명, 여자 36명으로 비슷한 비율을 보였으며 처음 진단받고 치료한 환자는 58명(87%)이었고 국소 재발하여 치료한 환자는 9명(13%)이었다. 조직학적으로 많은 부분을 차지한 육종은 지방육종으로 총 20명(30%)이었으며 그 다음으로 평활근 육종으로 9명(13%)을 차지하였다. 종양의 크기가 10 cm 보다 큰 환자의 수는 17명(25%)이었으며 19명(28%)의 환자에서 수술절제 단면 양성소견을 보였다. 조직결과에서 고등급이 43명으로 64%를 차지하였다. 육종이 발생하는 가장 흔한 장소는 하지로 35명(52%)이었으며 다음으로 차지한 곳이 몸통으로 9명(18%)이었다. 생존 기간 중앙값은 62.7개월(95% CI. 25.7-99.4)이었고, 무병생존기간 중앙값은 36.1개월(95% CI. 17.9-54.2)이었다. 수술만 한 집단에서의 생존 기간 중앙값과 무병생존기간 중앙값은 각각 51.2개월이고 21.1개월이었다. 이번 연구에서 전체 생존률과 관련된 예후인자는 종양의 크기, 활동도였다. 무병 생존기간과 관련된 인자는 종양위치와 절제단면이었는데, 수술 절제 단면 양성일 때, 종양의 위치가 두부, 천부몸통, 심부몸통에 위치하였을 때 무병 생존기간이 의미 있게 짧았다. 그러나 수술 후 치료 방법은 전체 생존기간이나 무병생존기간과 통계적으로 유의성이 없었다. 결론: 본 연구에서는 국소 연부조직 육종에서의 예후인자를 분석하였고, 종양이 클수록, 종양의 위치가 두부나 몸통에 위치할 때, 수술 절제 단면이 양성일 때, 그리고 환자의 일상생활 수행능력이 나쁠 때 예후가 나쁜 것으로 분석되었다.

Keywords

References

  1. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-1329. https://doi.org/10.1200/JCO.1992.10.8.1317
  2. Yang RS, Lane JM, Eilber FR, et al. High grade soft tissue sarcoma of the flexor fossae: size rather than compartmental status determine prognosis. Cancer 1995;76:1398-1405. https://doi.org/10.1002/1097-0142(19951015)76:8<1398::AID-CNCR2820760815>3.0.CO;2-B
  3. Eilber FR, Huth JF, Mirra J, Rosen G. Progress in the recognition and treatment of soft tissue sarcomas. Cancer 1990;65(Suppl 3):660-666. https://doi.org/10.1002/1097-0142(19900201)65:3+<660::AID-CNCR2820651308>3.0.CO;2-#
  4. Trovik CS, Bauer HC, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgicallytreated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000;36:710-716. https://doi.org/10.1016/S0959-8049(99)00287-7
  5. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 1994;259:1-31.
  6. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003;97:2530-2543. https://doi.org/10.1002/cncr.11365
  7. Pisters PW, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007;25:1003-1008. https://doi.org/10.1200/JCO.2006.09.8525
  8. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 2008;15:2739-2748. https://doi.org/10.1245/s10434-008-9970-6
  9. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 2006;56:282-291; quiz 314-315. https://doi.org/10.3322/canjclin.56.5.282
  10. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma: reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-1149. https://doi.org/10.1200/JCO.1994.12.6.1137
  11. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):80-84. https://doi.org/10.1159/000073366
  12. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 1994;10:347-356. https://doi.org/10.1002/ssu.2980100507
  13. Berlin O, Stener B, Angervall L, Kindblom LG, Markhede G, Odén A. Surgery for soft tissue sarcoma in the extremities: a multivariate analysis of the 6-26-year prognosis in 137 patients. Act Orthop Scand 1990;61:475-486. https://doi.org/10.3109/17453679008993568
  14. Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003;22:3515-3525. https://doi.org/10.1002/sim.1574
  15. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:3252-3259. https://doi.org/10.1200/JCO.1999.17.10.3252
  16. Stefanovski PD, Bidoli E, De Paoli A, Buonadonna A, Boz G, Libra M. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 2002;28:153-164. https://doi.org/10.1053/ejso.2001.1242
  17. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869-877. https://doi.org/10.1200/JCO.1996.14.3.869
  18. Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005;12:10-17. https://doi.org/10.1007/s10434-004-1171-3
  19. ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, Bastiaannet E, Suurmeijer AJ. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol 2007;14:222-229. https://doi.org/10.1245/s10434-006-9043-7